Stock Scorecard



Stock Summary for Bicycle Therapeutics Plc (BCYC) - $7.64 as of 6/18/2025 9:47:48 AM EST

Total Score

14 out of 30

Safety Score

32 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for BCYC

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BCYC

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BCYC

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BCYC

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BCYC (32 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BCYC

FDA Approved Anticancer Peptide Drug Conjugate Market Clinical Trials Insight 6/5/2025 5:37:00 PM
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday - Archer Aviation ( NYSE:ACHR ) , Amazon.com ( NASDAQ:AMZN ) 12/18/2024 3:20:00 PM
Texas Aligns with Trump's Bitcoin Strategy, Proposes Reserve with 5-Year Hold; Taiwan Semiconductor Projected to Dominate 67% of Foundry Market by 2025: IDC - Top Headlines Today While US Slept 12/13/2024 2:12:00 PM
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Bicycle Therapeutics ( NASDAQ:BCYC ) , Alumis ( NASDAQ:ALMS ) 12/13/2024 1:53:00 PM
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Bicycle Therapeutics ( NASDAQ:BCYC ) 12/13/2024 12:50:00 PM
Bicycle Therapeutics ( BCYC ) Soars 5.7%: Is Further Upside Left in the Stock? 10/14/2024 9:36:00 AM
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone - Bicycle Therapeutics ( NASDAQ:BCYC ) 9/6/2024 5:37:00 PM
What Makes Bicycle Therapeutics ( BCYC ) a New Buy Stock 8/9/2024 4:00:00 PM
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics ( BCYC ) : Can the Stock Really Move This High? 8/9/2024 1:55:00 PM
Are Medical Stocks Lagging Bicycle Therapeutics ( BCYC ) This Year? 6/27/2024 1:40:00 PM

Financial Details for BCYC

Company Overview

Ticker BCYC
Company Name Bicycle Therapeutics Plc
Country USA
Description Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 7.64
Price 4 Years Ago 60.87
Last Day Price Updated 6/18/2025 9:47:48 AM EST
Last Day Volume 494,671
Average Daily Volume 295,728
52-Week High 28.67
52-Week Low 6.10
Last Price to 52 Week Low 25.25%

Valuation Measures

Trailing PE N/A
Industry PE 22.38
Sector PE 40.20
5-Year Average PE -9.67
Free Cash Flow Ratio 0.46
Industry Free Cash Flow Ratio 17.66
Sector Free Cash Flow Ratio 31.91
Current Ratio Most Recent Quarter 14.86
Total Cash Per Share 16.60
Book Value Per Share Most Recent Quarter 10.70
Price to Book Ratio 0.75
Industry Price to Book Ratio 34.50
Sector Price to Book Ratio 30.01
Price to Sales Ratio Twelve Trailing Months 22.54
Industry Price to Sales Ratio Twelve Trailing Months 122.91
Sector Price to Sales Ratio Twelve Trailing Months 34.69
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 47,761,800
Market Capitalization 364,900,152
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 6.44%
Reported EPS 12 Trailing Months -3.16
Reported EPS Past Year -0.88
Reported EPS Prior Year -2.94
Net Income Twelve Trailing Months -203,266,630
Net Income Past Year -169,031,000
Net Income Prior Year -180,664,000
Quarterly Revenue Growth YOY -48.90%
5-Year Revenue Growth 20.65%
Operating Margin Twelve Trailing Months -704.00%

Balance Sheet

Total Cash Most Recent Quarter 792,973,000
Total Cash Past Year 879,520,000
Total Cash Prior Year 526,423,000
Net Cash Position Most Recent Quarter 762,064,000
Net Cash Position Past Year 848,822,000
Long Term Debt Past Year 30,698,000
Long Term Debt Prior Year 30,698,000
Total Debt Most Recent Quarter 30,909,000
Equity to Debt Ratio Past Year 0.96
Equity to Debt Ratio Most Recent Quarter 0.96
Total Stockholder Equity Past Year 793,060,000
Total Stockholder Equity Prior Year 370,932,000
Total Stockholder Equity Most Recent Quarter 740,333,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -182,128,666
Free Cash Flow Per Share Twelve Trailing Months -3.81
Free Cash Flow Past Year -165,959,000
Free Cash Flow Prior Year -63,557,000

Options

Put/Call Ratio 5.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.07
MACD Signal 0.05
20-Day Bollinger Lower Band 5.84
20-Day Bollinger Middle Band 9.09
20-Day Bollinger Upper Band 12.33
Beta 1.47
RSI 49.95
50-Day SMA 16.36
150-Day SMA 20.71
200-Day SMA 25.22

System

Modified 6/17/2025 6:38:17 PM EST